International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes. Journal of Clinical Oncology. 2008;26(25):4124–30.
2.
Swerdlow SH, Campo E, Harris NL. WHO Classification of Tumours of Haemotopoietic and Lymphoid Tissues. 2008.
3.
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.
4.
d’Amore F, Gaulard P, Trümper L, Corradini P, Kim WS, Specht L, et al. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2015;26:v108–15.
5.
Horwitz SM, Ansell SM, Ai WZ, Barnes J, Barta SK, Choi M, et al. NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018. Journal of the National Comprehensive Cancer Network. 2018;16(2):123–35.
6.
Biggar RJ, Engels EA, Frisch M, Goedert JJ. Risk of T-Cell Lymphomas in Persons With AIDS. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2001;26(4):371–6.
7.
de Jong D. Anaplastic Large-Cell Lymphoma in Women With Breast Implants. JAMA. 2008;300(17):2030.
8.
Gaulard P, de Leval L. Pathology of Peripheral T-Cell Lymphomas: Where Do We Stand? Seminars in Hematology. 2014;51(1):5–16.
9.
Asano N, Suzuki R, Kagami Y, Ishida F, Kitamura K, Fukutani H, et al. Clinicopathologic and Prognostic Significance of Cytotoxic Molecule Expression in Nodal Peripheral T-Cell Lymphoma, Unspecified. American Journal of Surgical Pathology. 2005;29(10):1284–93.
10.
Swerdlow SH, Jaffe ES, Brousset P, Chan JKC, de Leval L, Gaulard P, et al. Cytotoxic T-cell and NK-cell Lymphomas. American Journal of Surgical Pathology. 2014;38(10):e60–71.
11.
Perry AM, Warnke RA, Hu Q, Gaulard P, Copie-Bergman C, Alkan S, et al. Indolent T-cell lymphoproliferative disease of the gastrointestinal tract. Blood. 2013;122(22):3599–606.
12.
Petrella T, Maubec E, Cornillet-Lefebvre P, Willemze R, Pluot M, Durlach A, et al. Indolent CD8-positive Lymphoid Proliferation of the Ear. American Journal of Surgical Pathology. 2007;31(12):1887–92.
13.
Sun JC, Lanier LL. NK cell development, homeostasis and function: parallels with CD8+ T cells. Nature Reviews Immunology. 2011;11(10):645–57.
14.
Lanier LL, Testi R, Bindl J, Phillips JH. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. The Journal of experimental medicine. 1989;169(6):2233–8.
15.
Chan J, Tsang W, Ng C. Clarification of CD3 immunoreactivity in nasal T/natural killer cell lymphomas: the neoplastic cells are often CD3 epsilon+ [letter; comment]. Blood. 1996;87(2):839–41.
16.
Felgar RE, Macon WR, Kinney MC. TIA-1 expression in lymphoid neoplasms. Identification of subsets with cytotoxic T lymphocyte or natural killer cell differentiation. Am J Pathol. 1997;150(6):1893–900.
17.
de Leval L, Rickman DS, Thielen C, Reynies A de, Huang YL, Delsol G, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109(11):4952–63.
18.
Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T, Kucuk C, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood. 2010;115(5):1026–36.
19.
Cuadros M, Dave SS, Jaffe ES, Honrado E, Milne R, Alves J, et al. Identification of a Proliferation Signature Related to Survival in Nodal Peripheral T-Cell Lymphomas. Journal of Clinical Oncology. 2007;25(22):3321–9.
20.
Dupuis J, Emile JF, Mounier N, Gisselbrecht C, Martin-Garcia N, Petrella T, et al. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d’Etude des Lymphomes de l’Adulte (GELA) study. Blood. 2006;108(13):4163–9.
21.
Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, et al. Marker Expression in Peripheral T-Cell Lymphoma: A Proposed Clinical-Pathologic Prognostic Score. Journal of Clinical Oncology. 2006;24(16):2472–9.
22.
Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014;123(19):2915–23.
23.
de Leval L, Gaulard P. Pathobiology and Molecular Profiling of Peripheral T-Cell Lymphomas. Hematology. 2008;2008(1):272–9.
24.
Rodríguez-Pinilla SM, Atienza L, Murillo C, Pérez-Rodríguez A, Montes-Moreno S, Roncador G, et al. Peripheral T-cell Lymphoma With Follicular T-cell Markers. American Journal of Surgical Pathology. 2008;32(12):1787–99.
25.
Dupuis J, Boye K, Martin N, Copie-Bergman C, Plonquet A, Fabiani B, et al. Expression of CXCL13 by Neoplastic Cells in Angioimmunoblastic T-Cell Lymphoma (AITL). The American Journal of Surgical Pathology. 2006;30(4):490–4.
26.
Grogg KL, Morice WG, Macon WR. Spectrum of bone marrow findings in patients with angioimmunoblastic T‐cell lymphoma. British Journal of Haematology. 2007;137(5):416–22.
27.
Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nature Genetics. 2014;46(2):171–5.
28.
Attygalle AD, Kyriakou C, Dupuis J, Grogg KL, Diss TC, Wotherspoon AC, et al. Histologic Evolution of Angioimmunoblastic T-cell Lymphoma in Consecutive Biopsies: Clinical Correlation and Insights Into Natural History and Disease Progression. American Journal of Surgical Pathology. 2007;31(7):1077–88.
29.
Bayle C, Charpentier A, Duchayne E, Manel A, Pages M, Robert A, et al. Leukaemic presentation of small cell variant anaplastic large cell lymphoma: report of four cases. British Journal of Haematology. 1999;104(4):680–8.
30.
Kinney MC, Collins RD, Greer JP, Whitlock JA, Sioutos N, Kadin ME. A Small-Cell-Predominant Variant of Primary Ki-1 (CD30)+ T-Cell Lymphoma. The American Journal of Surgical Pathology. 1993;17(9):859–68.
31.
Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124(9):1473–80.
32.
Clemens MW, Brody GS, Mahabir RC, Miranda RN. How to Diagnose and Treat Breast Implant–Associated Anaplastic Large Cell Lymphoma. Plastic & Reconstructive Surgery. 2018;141(4):586e–99e.
33.
Loch-Wilkinson A, Beath KJ, Knight RJW, Wessels WLF, Magnusson M, Papadopoulos T, et al. Breast Implant–Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand: High-Surface-Area Textured Implants Are Associated with Increased Risk. Plastic & Reconstructive Surgery. 2017;140(4):645–54.
34.
Kim B, Roth C, Young VL, Chung KC, van Busum K, Schnyer C, et al. Anaplastic Large Cell Lymphoma and Breast Implants. Plastic and Reconstructive Surgery. 2011;128(3):629–39.
35.
Yamaguchi M, Oguchi M, Suzuki R. Extranodal NK/T-cell lymphoma: Updates in biology and management strategies. Best Practice & Research Clinical Haematology. 2018;31(3):315–21.
36.
Park S, Ko YH. Epstein–Barr virus‐associated T/natural killer‐cell lymphoproliferative disorders. The Journal of Dermatology. 2014;41(1):29–39.
37.
Tan SY, Ooi AS, Ang MK, Koh M, Wong JC, Dykema K, et al. Nuclear expression of MATK is a novel marker of type II enteropathy-associated T-cell lymphoma. Leukemia. 2011;25(3):555–7.
38.
Quintanilla‐Martinez L. The 2016 updated WHO classification of lymphoid neoplasias. Hematological Oncology. 2017;35(S1):37–45.
39.
Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496–504.
40.
Ferreri AJM, Govi S, Pileri SA. Hepatosplenic gamma-delta T-cell lymphoma. Critical Reviews in Oncology/Hematology. 2012;83(2):283–92.
41.
Ellin F, Landström J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124(10):1570–7.
42.
Schmitz N, Trümper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116(18):3418–25.
43.
Carson KR, Horwitz SM, Pinter‐Brown LC, Rosen ST, Pro B, Hsi ED, et al. A prospective cohort study of patients with peripheral T‐cell lymphoma in the United States. Cancer. 2017;123(7):1174–83.
44.
d’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01. Journal of Clinical Oncology. 2012;30(25):3093–9.
45.
Schmitz N, de Leval L. How I manage peripheral T‐cell lymphoma, not otherwise specified and angioimmunoblastic T‐cell lymphoma: current practice and a glimpse into the future. British Journal of Haematology. 2017;176(6):851–66.
46.
Petković I. Current trends in the treatment of primary mediastinal large B-cell lymphoma – an overview. Współczesna Onkologia. 2015;6:428–35.
47.
Maeda Y, Nishimori H, Yoshida I, Hiramatsu Y, Uno M, Masaki Y, et al. Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707. Haematologica. 2017;102(12):2097–103.
48.
Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Annals of Oncology. 2014;25(11):2211–7.
49.
Zinzani PL, Magagnoli M, Bendandi M, Orcioni GF, Gherlinzoni F, Albertini P, et al. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Annals of Oncology. 1998;9(12):1351–3.
50.
Mahadevan D, Unger JM, Spier CM, Persky DO, Young F, LeBlanc M, et al. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T‐cell non‐Hodgkin lymphoma. Cancer. 2013;119(2):371–9.
51.
Li L, Duan W, Zhang L, Li X, Fu X, Wang X, et al. The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus <scp>CHOP</scp> in patients with newly diagnosed peripheral T‐cell lymphoma with analysis of biomarkers. British Journal of Haematology. 2017;178(5):772–80.
52.
Horwitz S, O’Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. The Lancet. 2019;393(10168):229–40.
53.
Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, et al. A phase <scp>II</scp> study of cyclophosphamide, etoposide, vincristine and prednisone ( <scp>CEOP</scp> ) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T‐cell lymphoma ( <scp>PTCL</scp> ): final results from the T‐ cell consortium trial. British Journal of Haematology. 2016;172(4):535–44.
54.
Kim SJ, Yoon DH, Kang HJ, Kim JS, Park SK, Kim HJ, et al. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial. European Journal of Cancer. 2012;48(17):3223–31.
55.
Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study. Journal of Clinical Oncology. 2012;30(18):2190–6.
56.
Zinzani PL, Venturini F, Stefoni V, Fina M, Pellegrini C, Derenzini E, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Annals of Oncology. 2010;21(4):860–3.
57.
Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, et al. Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial. Journal of Clinical Oncology. 2013;31(1):104–10.
58.
Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M, et al. Graft-Versus-Lymphoma Effect in Relapsed Peripheral T-Cell Non-Hodgkin’s Lymphomas After Reduced-Intensity Conditioning Followed by Allogeneic Transplantation of Hematopoietic Cells. Journal of Clinical Oncology. 2004;22(11):2172–6.
59.
Kanakry JA, Kasamon YL, Gocke CD, Tsai HL, Davis-Sproul J, Ghosh N, et al. Outcomes of Related Donor HLA-Identical or HLA-Haploidentical Allogeneic Blood or Marrow Transplantation for Peripheral T Cell Lymphoma. Biology of Blood and Marrow Transplantation. 2013;19(4):602–6.
60.
Kyriakou C, Canals C, Finke J, Kobbe G, Harousseau JL, Kolb HJ, et al. Allogeneic Stem Cell Transplantation Is Able to Induce Long-Term Remissions in Angioimmunoblastic T-Cell Lymphoma: A Retrospective Study From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology. 2009;27(24):3951–8.
61.
Feyler S, Prince HM, Pearce R, Towlson K, Nivison-Smith I, Schey S, et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplantation. 2007;40(5):443–50.
62.
Kim WS, Song SY, Ahn YC, Ko YH, Baek CH, Kim DY, et al. CHOP followed by involved field radiation: Is it optimal for localized nasal natural killer/T-cell lymphoma? Annals of Oncology. 2001;12(3):349–52.
63.
Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012;120(15):2973–80.
64.
Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood. 2011;117(6):1834–9.
65.
Ávila Milord AA, Aguilar Hernández MM, Demichelis Gómez R, Agreda Vásquez GP. Effectiveness of L-asparaginase-based regimens compared to anthracycline-based regimens in newly diagnosed extranodal NK/T-cell lymphoma, nasal type: a single Mexican center experience. Blood Research. 2018;53(3):210.
66.
BU S, YUAN F, WEI X, YIN Q, LI Y, MI R, et al. L-asparaginase-based regimen as a first-line treatment for newly diagnosed nasal type extranodal natural killer cell/T-cell lymphoma. Experimental and Therapeutic Medicine. 2016;11(6):2437–45.
67.
Yang L, Liu H, Xu X hong, Wang X feng, Huang H ming, Shi W yu, et al. Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)/T cell lymphoma, nasal type. Medical Oncology. 2013;30(4).
68.
Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, et al. Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: An Updated Analysis of the Japan Clinical Oncology Group Study JCOG0211. Journal of Clinical Oncology. 2012;30(32):4044–6.
69.
Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017;129(17):2437–42.
70.
Hari P, Raj RV, Olteanu H. Targeting CD38 in Refractory Extranodal Natural Killer Cell–T-Cell Lymphoma. New England Journal of Medicine. 2016;375(15):1501–2.
71.
Kim HK, Moon SM, Moon JH, Park JE, Byeon S, Kim WS. Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin. Blood Research. 2015;50(4):254.
72.
Poon LM, Kwong YL. Complete remission of refractory disseminated NK/T cell lymphoma with brentuximab vedotin and bendamustine. Annals of Hematology. 2016;95(5):847–9.
73.
Malamut G, Chandesris O, Verkarre V, Meresse B, Callens C, Macintyre E, et al. Enteropathy associated T cell lymphoma in celiac disease: A large retrospective study. Digestive and Liver Disease. 2013;45(5):377–84.
74.
Nijeboer P, de Baaij LR, Visser O, Witte BI, Cillessen SAGM, Mulder CJ, et al. Treatment response in enteropathy associated <scp>T</scp>‐cell lymphoma; survival in a large multicenter cohort. American Journal of Hematology. 2015;90(6):493–8.
75.
Jantunen E, Boumendil A, Finel H, Luan JJ, Johnson P, Rambaldi A, et al. Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT. Blood. 2013;121(13):2529–32.
76.
Gentille C, Qin Q, Barbieri A, Sai Ravi P, Iyer S. Use of PEG-asparaginase in monomorphic epitheliotropic intestinal T-cell lymphoma, a disease with diagnostic and therapeutic challenges. ecancermedicalscience. 11.
77.
Voss MH, Lunning MA, Maragulia JC, Papadopoulos EB, Goldberg J, Zelenetz AD, et al. Intensive Induction Chemotherapy Followed by Early High-Dose Therapy and Hematopoietic Stem Cell Transplantation Results in Improved Outcome for Patients with Hepatosplenic T-Cell Lymphoma: A Single Institution Experience. Clinical Lymphoma Myeloma and Leukemia. 2013;13(1):8–14.
78.
O’Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, et al. Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study. Journal of Clinical Oncology. 2011;29(9):1182–9.
79.
Qi W, Spier C, Liu X, Agarwal A, Cooke LS, Persky DO, et al. Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. Leukemia Research. 2013;37(4):434–9.
80.
Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, et al. Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. Journal of Clinical Oncology. 2015;33(21):2399–404.
81.
Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, et al. Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas. Journal of Clinical Oncology. 2014;32(1):44–50.
82.
Islam S, Vick E, Huber B, Morales C, Spier C, Cooke L, et al. Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy. Oncotarget. 2017;8(59):100326–38.
83.
Shustov A, Coiffier B, Horwitz S, Sokol L, Pro B, Wolfson J, et al. Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials. Leukemia & Lymphoma. 2017;58(10):2335–41.
84.
O’Connor OA, Falchi L, Lue JK, Marchi E, Kinahan C, Sawas A, et al. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. Blood. 2019;134(17):1395–405.
85.
O’Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, et al. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. Journal of Clinical Oncology. 2015;33(23):2492–9.
86.
Gambacorti Passerini C, Farina F, Stasia A, Redaelli S, Ceccon M, Mologni L, et al. Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase–Positive Lymphoma Patients. JNCI: Journal of the National Cancer Institute. 2014;106(2).
87.
Thanarajasingam G, Edell ES, Markovic SM. Complete Response of Anaplastic Lymphoma Kinase–Mutated Refractory Extranodal Natural Killer/T-Cell Lymphoma to Crizotinib. Mayo Clinic Proceedings. 2016;91(9):1319–20.
88.
Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, et al. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2018;131(8):888–98.
89.
Oki Y, Haverkos B, Zain JM, Lechowicz MJ, Devata S, Korman NJ, et al. Tenalisib, a dual PI3K δ/γ inhibitor: Safety and efficacy results from an on-going phase I/Ib study in relapsed/refractory T-cell lymphoma. Journal of Clinical Oncology. 2018;36(15_suppl):7510–7510.
90.
Delarue R, Dupuis J, Sujobert P, Barbieux S, Marçais A, Tournilhac O, et al. Treatment with Hypomethylating Agent 5-Azacytidine Induces Sustained Response in Angioimmunoblastic T Cell Lymphomas. Blood. 2016;128(22):4164–4164.
91.
Makita S, Maeshima AM, Maruyama D, Izutsu K, Tobinai K. Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review. OncoTargets and Therapy. Volume 11:2287–93.
92.
Witzig T, Sokol L, Jacobsen E, Advani R, Mondejar R, Piris M, et al. PRELIMINARY RESULTS FROM AN OPEN‐LABEL, PHASE II STUDY OF TIPIFARNIB IN RELAPSED OR REFRACTORY PERIPHERAL T‐CELL LYMPHOMA. Hematological Oncology. 2017;35(S2):251–2.
93.
Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, et al. Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma. Journal of Clinical Oncology. 2014;32(11):1157–63.
94.
Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald AP, Repp R, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004;103(8):2920–4.
95.
Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, et al. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. Journal of Clinical Oncology. 2016;34(23):2698–704.
96.
Amengual JE, Lichtenstein R, Rojas C, Sawas A, Deng C, Lichtenstien E, et al. The Pralatrexate - Romidepsin Doublet: A Well Tolerated and Highly Effective Combination for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. Blood. 2016;128(22):1824–1824.
97.
Mehta-Shah N, Lunning MA, Boruchov AM, Ruan J, Nair S, Lynch P, et al. A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Activity in T-cell lymphoma. Journal of Clinical Oncology. 2015;33(15_suppl):8521–8521.
98.
Holkova B, Yazbeck V, Kmieciak M, Bose P, Ma S, Kimball A, et al. A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. Leukemia & Lymphoma. 2017;58(6):1349–57.
99.
Mehta-Shah N, Moskowitz AJ, Lunning M, Lynch P, Scheuerman M, Kumar A, et al. A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory T-Cell Lymphomas. Blood. 2016;128(22):2991–2991.
100.
Fanale MA, Hagemeister FB, Fayad L, Oki Y, Fowler N, Romaguera J, et al. A Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas. Blood. 2014;124(21):1744–1744.
101.
Moskowitz AJ, Koch R, Mehta-Shah N, Myskowski P, Kheterpal M, Dogan A, et al. In Vitro, In Vivo, and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-δ,γ Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma. Blood. 2017;130(Suppl_1):819–819.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
